Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 7/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.40 |
| ▸ | AR | P10275 | 5/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2948487 | 0.86 | CSNK2A2 (0.41) | VDRARESR1ESR2L3MBTL1 | |
| SCHEMBL2942389 | 0.84 | ESR1 (0.56) | VDRHDAC6ARESR1ESR2 | |
| SCHEMBL2941251 | 0.80 | VDR (0.67) | VDRHDAC6ARHDAC3 | |
| SCHEMBL9958325 | 0.80 | CA1 (0.45) | L3MBTL1ALDH1A1 | |
| SCHEMBL2948695 | 0.80 | HDAC6 (0.63) | VDRHDAC6ARHDAC3 | |
| SCHEMBL13236435 | 0.79 | HDAC6 (0.45) | VDRHDAC6ARHDAC3 | |
| SCHEMBL13264568 | 0.79 | HDAC6 (0.45) | VDRHDAC6ARHDAC3 | |
| SCHEMBL13264691 | 0.78 | HDAC6 (0.46) | VDRHDAC6AR | |
| SCHEMBL2950878 | 0.77 | ESR1 (0.49) | VDRHDAC6ARESR1ESR2 | |
| SCHEMBL25955803 | 0.76 | ESR1 (0.54) | ARESR1ESR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750184-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750184-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2010-07-06 | — | — | US | disclosed |
| US-7750184-B2 | Vitamin D receptor modulators | ELI LILLY AND COMPANY (US) | 2010-07-06 | — | — | US | disclosed |
| US-20060293385-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY, AN INDIANA CORPORATION | 2006-12-28 | — | — | US | disclosed |
| EP-1687265-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005051898-A2 | VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293385-A1 | Vitamin d receptor modulators | VDR, CYP24A1, CYP2R1 | VDR 1/4885HDAC6 4192/4885AR 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.